SavedAdd your journal

Journals / MN Oftalmoloji / 2012 / Cilt: 19 - Sayı: 1

Effectiveness of travoprost %0.004 and timolol maleate %0.5 fixed combination in patients with primary open-angle glaucoma

Primer açık açılı glokom olgularında travaprost %0,004 ve timolol maleat %0,5 sabit kombinasyonunun etkinliğinin değerlendirilmesi

Gökhan YEŞİLYURT
Pages
4–8
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: TTFC provides effective IOP control with low rates of side effects besides offering the advantages of fixed combinations of anti-glaucomatous agents.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To evaluate the intraocular pressure (IOP) lowering effect and adverse effects of travoprost 0.004% and timolol maleate 0.5% fixed combination (TTFC) in patients with Primary Open-Angle Glaucoma (POAG).
📊
Key Findings & Data:Material and Method: In this prospective study, 96 eyes of 48 patients with the diagnosis of POAG who haven’t received any glaucoma medication were included.
💡
Conclusion & Impact:Conclusion: TTFC provides effective IOP control with low rates of side effects besides offering the advantages of fixed combinations of anti-glaucomatous agents.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: To evaluate the intraocular pressure (IOP) lowering effect and adverse effects of travoprost 0.004% and timolol maleate 0.5% fixed combination (TTFC) in patients with Primary Open-Angle Glaucoma (POAG). Material and Method: In this prospective study, 96 eyes of 48 patients with the diagnosis of POAG who haven&#8217;t received any glaucoma medication were included. This group was treated with TTFC for 6 months. Results: Pre and 6th month IOP was;24.30±1.45 mmHg and 12.43±1.48 mmHg respectively. After 6 months of treatment the reduction of IOP was statistically significant. Compared with pre-treatment, at 3rd month diurnal variation was significantly lower (p<0.01). Systemic adverse effect was not observed in any patients. Mild and moderate conjunctival hyperemia was observed in 18 eyes, severe conjunctival hyperaemia was observed in one eye, ocular irritation was observed in 15 eyes, heterechromia in iris in 3 eyes, hypertrichosis observed in 12 eyes. Conclusion: TTFC provides effective IOP control with low rates of side effects besides offering the advantages of fixed combinations of anti-glaucomatous agents.

Özet

Amaç: Primer açık açılı glokom (PAAG) olgularında, travaprost %0,004 ve timolol maleat %0,5 sabit kombinasyonunun (TTSK) göz içi basıncını (GİB) düşürmedeki etkisini, oküler ve sistemik yan etkilerini değerlendirmek. Gereç ve Yöntem: Primer açık açılı glokom tanısı almış 48 hastanın 96 gözü prospektif olarak incelendi. İlaç tedavisi 6 ay boyunca devam edildi. Bulgular: Başlangıç ve 6.ay GİB değerleri 24,30±1,45 mmHg ve 12,43±1,48 mmHg idi. Tedavinin 6. ayında GİB’ında istatistiksel olarak anlamlı bir düşüş görüldü. 3. ayda başlangıç GİB’na göre gün içi dalgalanma düzeyinde istatistiksel olarak anlamlı bir düşüş saptandı (p<0,05). Hiç bir hastada sistemik yan etki görülmezken, 18 hastada hafif ve orta şiddette değişen konjunktiva hiperemisi, 1 hastada ağır konjunktival hiperemi ve kapakta hiperemi, 15 hastada oküler iritasyon, 3 hastada iriste renk değişikliği, ve 12 hastada kirpiklerde uzama saptandı. Sonuç: Primer açık açılı glokom hastalarında kombine preparatların tedavide sağladığı avantajları sunan TTSK göz içi basıncını etkili olarak düşüşün yanında, yan etki oranının düşüklüğü hasta uyumunu artırmaktadır.

🔖

Cite This Article

YEŞİLYURT, G. (2012). Effectiveness of travoprost %0.004 and timolol maleate %0.5 fixed combination in patients with primary open-angle glaucoma. MN Oftalmoloji, Cilt: 19 - Sayı: 1, 4–8. https://ajindex.com/articles/295699

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. American Academy of Ophthalmology, Basic and clinical science course, Glaucoma 2000-2001;Chapter 2
  2. Fraser S, Bunce C, Wormald R. Risk factors for late presentation in chronic glaucoma. Invest Ophthalmol 1999;40:1-7
  3. Ertürk H. Primer glokomda medikal tedavi. T Klin Oftalmol 2004;13:76-86
  4. Lee PS, Gagliuso DJ, Serie JB. Medical therapy for glaucoma. In Choplin NT: Atlas of Glaucoma. Informa UK Ltd London. 2007;221-38
  5. Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 1998;7:95-104
  6. Quigley HA: Number of people with glaucoma worlwide. Br J Ophthalmol 1999;80:389-93
  7. Leske MC, Heijl A, Hussein M, et al. Factors of glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2002;121:48-56
  8. Mao LK, Steward WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991;111:51-4
  9. The AGIS Investigators. Advenced Glaucoma Intervention Study (AGIS
  10. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
  11. Shin DH, Hughes BA, Song MS, et al. Primary glaucoma triple procedure with or without adjunctive mitomycin. Prognostic factors for filtration faulire. Ophthalmology 1996;103:1925-33
  12. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrop for glaucoma. Ophthalmic Surg 1995;26:233-6
  13. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2. analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994;78:899- 902
  14. Arıcı MK, Topaklara A, Güler C, ve ark. Latanoprost ve betaxolol kombinasyonunun göziçi basıncı üzerine kısa süreli etkisinin incelenmesi. MN Oftalmol 1999;6:123-6
  15. Elgin U, İlhan B, Batman A, ve ark. Primer açık açılı glokomda akşam veya sabah tek doz uygulanan latanaprostun göziçi basıncına etkisinin timolol maleat ile karşılaştırılması. T Oft Gaz 2003;33:260-4
  16. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening and morning. A comparison with timolol. Ophthalmology 1995;102:1743-52
  17. McCannel CA, Heinrich SR, Brubaker RF. Acetazolamide but not timolol lowers aqueous humor flow in sleeping humans.